2694P Long-term efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): 2-year results from the MOTION phase III trial
Sebastian Bauer, Vivek A. Bhadri, H. Gelderblom, S. Stacchiotti, Andrew J. Wagner, Meike van de Sande, Nicholas M. Bernthal, Albiruni Ryan Abdul Razak, A. Italiano, M. Ahmed, A. Le Cesne, Christopher Tait, Fiona Zarins, N. Zeringo, B. Harrow, Manu Sharma, M.L. Sherman, Jean Yves Blay, W.D. Tap (2025). 2694P Long-term efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): 2-year results from the MOTION phase III trial. , 36, DOI: https://doi.org/10.1016/j.annonc.2025.08.3305.
